# About This Site

> TB-500 Safe is an independent editorial project that summarizes the peer-reviewed literature on TB-500 and Thymosin Beta-4 — focused on safety, evidence quality, and the gaps in the research record.

## What TB-500 Safe is

TB-500 Safe is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 and its parent compound, Thymosin Beta-4 (Tβ4). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site name names a question — one the research literature only partially answers. The "safe" modifier is not marketing. It is an orientation: this is a site that takes the safety questions seriously and answers them honestly from the published record.

## Our editorial approach

Every quantitative claim on this site traces to a specific peer-reviewed citation in the references list. We distinguish the TB-500 fragment (Ac-LKKTETQ) from the full Tβ4 protein throughout — a distinction that matters because the only published Phase I human trial covers the full protein, not the heptapeptide fragment [16].

We do not overstate favorable findings. We do not minimize unfavorable ones. The angiogenesis-and-cancer concern is documented at the same weight as the tissue repair findings.

## What this site is not

TB-500 Safe is not a clinic and does not provide medical advice. This site does not sell TB-500 or any other compound. It does not provide sourcing recommendations. Research findings summarized here are preclinical unless explicitly stated otherwise. Nothing on this site should be read as a recommendation for any human use of any compound.

## References

[16] Wang X, et al. Phase I study of recombinant human thymosin β4. J Cell Mol Med. 2021. DOI: 10.1111/jcmm.16693

---

Peer-reviewed findings on TB-500, read warmly and honestly — the evidence gaps are noted alongside the findings, and no clinic sits behind this page.